PO.CL01.07 · 临床研究

尿液细胞游离RNA捕获膀胱癌中反映肿瘤的长基因间非编码RNA和环状RNA程序

Urine cell-free RNA captures tumor-reflective long intergenic noncoding and circular RNA programs in bladder cancer

海报缩略图:尿液细胞游离RNA捕获膀胱癌中反映肿瘤的长基因间非编码RNA和环状RNA程序
编号 1133 展板 14 时间 4/19 02:00–05:00 区域 Section 44 主讲 Pradeep Chauhan, PhD
分会场 Liquid Biopsies: Circulating Nucleic Acids 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Pradeep Chauhan1, Li Lin2, Irfan Alahi1, Jessica Linford1, Lilli J. Greiner1, Ayesha Hashmi1, Anushka Viswanathan1, Nathan Colon3, Faridi Qaium1, Peter K. Harris2, John Sheng2, Jacob J. Orme1, Eric H. Kim4, Zachary L. Smith5, Woodson Smelser2, Christopher A. Maher2, Aadel A. Chaudhuri1

1Mayo Clinic, Rochester, MN,2Washington University School of Medicine, Saint Louis, MO,3Hoag Foundation, Newport Beach, CA,4University of Nevada Reno, Reno, NV, Reno, NV,5Advent Health, Orlando, FL

摘要 Abstract

中文摘要
引言:长基因间非编码RNA(lincRNA)和环状(circ)RNA已被证明在癌变和肿瘤进展中发挥关键作用。尿液是一种有前景的反映肿瘤信号的来源,这些信号直接从膀胱癌(BC)患者的尿路上皮微环境中脱落。在此,我们评估了50例局限性BC患者队列中的尿液细胞游离(cf)RNA转录组。 方法:共纳入50例局限性BC患者和24名健康成人。对术前尿液(在根治性膀胱切除术当天收集)进行处理,从尿液上清中分离cfRNA。使用基于Illumina转座酶片段化的RNA富集工作流程制备文库,并在NovaSeq X上测序,每样本达1亿双端读长。每样本的FASTQ文件被合并,并用RNA-SeQC和Samtools进行质控。使用STAR将读长比对到GRCh38/hg38,并使用Feature Counts生成基因计数。使用DESeq2进行线性差异表达分析(DEA)。在发现阶段,我们使用TCGA-BLCA和健康尿液cfRNA样本的随机半数,同时对尿液BC cfRNA与对照的随机半数进行第二次DEA;在其余样本中验证重叠的上调基因。对于环状(circ)RNA,使用来自MiOncoCirc的注释;保留具有≥5个支持读长的连接点,并用edgeR进行DEA。 结果:在本研究中,中位年龄为68岁,80%(40/50)为男性。在队列中,66%(33/50)为肌层浸润性膀胱癌(MIBC),其中54%接受了新辅助化疗。对TCGA-BLCA肿瘤和BC尿液cfRNA的差异表达分析鉴定出27个共同上调的基因,其中27个共享基因中有23个引人注目地为长基因间非编码RNA(lincRNA)。这些BC/尿液特异性lincRNA——包括LINC00930、LINC01004、DLG5-AS1、APTR、PSORS1C3和SERPINB9P1——在增殖、EMT、代谢和免疫信号传导中具有已知作用。除lincRNA外,BC/尿液中反映肿瘤的编码转录本在自噬方面富集,由MAP1LC3B2驱动。TCGA-BLCA生存分析显示LINC00930和PSORS1C3与更差的总生存期相关。超越线性RNA序列,对BC患者尿液circRNA的分析揭示了强烈的癌症特异性失调模式,与健康对照相比有77个circRNA显著上调。上调的尿液circRNA来源于参与BC相关通路的宿主基因,包括侵袭(DOCK1、ARHGAP5)、自噬/ER应激(VMP1、ERN1)和管腔分化(GRHL2、ESRP1)。 结论:细胞游离RNA分析揭示了膀胱癌患者尿液中一种独特的转录组特征,包括由lincRNA和circRNA驱动的差异性自噬、EMT、增殖、代谢、分化和免疫信号传导程序。
查看英文原文 English abstract
Introduction: Long intergenic noncoding RNAs (lincRNAs) and circular (circ) RNAs have been shown to play key roles in carcinogenesis and tumor progression. Urine represents a promising source of tumor-reflective signals shed directly from the urothelial microenvironment in bladder cancer (BC) patients. Here, we evaluate the urine cell-free (cf) RNA transcriptome in a cohort of 50 patients with localized BC. Methods: A total of 50 localized BC patients and 24 healthy adults were enrolled. Pre-operative urine (collected on the day of radical cystectomy) was processed to isolate cfRNA from urine supernatant. Libraries were prepared using an Illumina tagmentation-based RNA enrichment workflow and sequenced to 100M paired-end reads per sample on a NovaSeq X. FASTQ files were concatenated per sample and QC-checked with RNA-SeQC and Samtools. Reads were aligned to GRCh38/hg38 with STAR, and gene counts were generated using Feature Counts. Linear differential expression analysis (DEA) was performed with DESeq2. For discovery we used random halves of TCGA-BLCA and healthy urine cfRNA samples, alongside a second DEA with random halves of urine BC cfRNA vs. controls; overlapping upregulated genes were validated in the remaining samples. For circular (circ) RNAs, annotations from MiOncoCirc were used; junctions with ≥5 supporting reads were retained, and DEA was conducted with edgeR. Results: In this study, the median age was 68 years, and 80% (40/50) were male. Among the cohort, 66% (33/50) had muscle-invasive bladder cancer (MIBC), of whom 54% received neoadjuvant chemotherapy. Differential expression analysis of TCGA-BLCA tumors and BC urine cfRNA, identified 27 genes commonly upregulated, with 23 of the 27 shared genes strikingly being long intergenic noncoding RNAs (lincRNAs). These BC/urine-specific lincRNAs-including LINC00930, LINC01004, DLG5-AS1, APTR, PSORS1C3, and SERPINB9P1-have known roles in proliferation, EMT, metabolism, and immune signaling. Outside of lincRNAs, tumor-reflective coding transcripts in BC/urine were enriched for autophagy, driven by MAP1LC3B2.TCGA-BLCA survival analysis showed that LINC00930 and PSORS1C3 were associated with worse overall survival. Expanding beyond linear RNA sequences, analysis of urine circRNAs from BC patients revealed a strong cancer-specific dysregulation pattern, with 77 circRNAs significantly upregulated compared with healthy controls. Upregulated urine circRNAs arose from host genes involved in BC-relevant pathways, including invasion ( DOCK1 , ARHGAP5 ), autophagy/ER stress ( VMP1 , ERN1 ), and luminal differentiation ( GRHL2 , ESRP1 ). Conclusion: Cell-free RNA profiling reveals a distinct transcriptomic signature including differential lincRNA- and circRNA-driven autophagy, EMT, proliferation, metabolic, differentiation, and immune signaling programs in the urine of bladder cancer patients.
利益披露 Disclosure
P. Chauhan, NA Patent, Patent related to cancer biomarkers.. L. Lin, None.. I. Alahi, None.. J. Linford, None.. L. J. Greiner, None.. A. Hashmi, None.. A. Viswanathan, None.. N. Colon, None.. F. Qaium, None.. P. K. Harris, None.. J. Sheng, None. J. J. Orme, Janux Therapeutics Clinical trial support. NaNotics support and/or research and consulting support. Nexus Global support and/or research and consulting support. Genentech support and/or research and consulting support. Partner Therapeutics support and/or research and consulting support. Johnson & Johnson Research Support. E. H. Kim, None.. Z. L. Smith, None.. W. Smelser, None.. C. A. Maher, None. A. A. Chaudhuri, Droplet Biosciences Leadership role, Licensed technology, and Ownership interest. Tempus / Tempus AI Licensed technology, Consultant / Advisor and Research Support. LiquidCell Dx Leadership role, Licensed technology, and Ownership interest. Biocognitive Labs Licensed technology . Roche Honoraria, Consultant / Advisor and Research support. Geneoscopy Stock Option, Consultant / Advisor. NuProbe Consultant / Advisor. Illumina Consultant / Advisor and Research support. Invitae Consultant / Advisor. Myriad Genetics Consultant / Advisor. Daiichi Sankyo Consultant / Advisor. AstraZeneca Consultant / Advisor. AlphaSights Consultant / Advisor. DeciBio Consultant / Advisor. Guidepoint Consultant / Advisor. Foundation Medicine Honoraria. Agilent Honoraria. Binaytara Foundation Honoraria. Dava Oncology Honoraria. NA Patent, cancer biomarker.

← 返回 AACR 2026 检索